LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Search

West Pharmaceutical Services Inc

Aperta

SettoreSettore sanitario

277.46 0.35

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

272.95

Massimo

277.77

Metriche Chiave

By Trading Economics

Entrata

8.2M

140M

Vendite

38M

804M

P/E

Media del settore

40.651

79.874

EPS

1.96

Rendimento da dividendi

0.31

Margine di Profitto

17.406

Dipendenti

10,600

EBITDA

19M

217M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+26.13% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.31%

2.31%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-56M

20B

Apertura precedente

277.11

Chiusura precedente

277.46

Notizie sul Sentiment di mercato

By Acuity

50%

50%

168 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

West Pharmaceutical Services Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 nov 2025, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 nov 2025, 15:32 UTC

Acquisizioni, Fusioni, Takeovers

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 nov 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 nov 2025, 23:50 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 nov 2025, 16:05 UTC

Discorsi di Mercato

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 nov 2025, 16:04 UTC

Discorsi di Mercato

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 nov 2025, 15:54 UTC

Acquisizioni, Fusioni, Takeovers

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 nov 2025, 15:44 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 nov 2025, 15:43 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 nov 2025, 15:42 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 nov 2025, 15:41 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 nov 2025, 15:11 UTC

Discorsi di Mercato

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 nov 2025, 14:26 UTC

Discorsi di Mercato

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 nov 2025, 14:11 UTC

Discorsi di Mercato

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 nov 2025, 14:11 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

27 nov 2025, 13:35 UTC

Discorsi di Mercato

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 nov 2025, 13:33 UTC

Discorsi di Mercato

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 nov 2025, 13:22 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

27 nov 2025, 13:22 UTC

Discorsi di Mercato

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 nov 2025, 13:17 UTC

Discorsi di Mercato

LVMH Should Be Able to Recover Next Year -- Market Talk

27 nov 2025, 11:13 UTC

Discorsi di Mercato

European Gas Prices Come Under Pressure -- Market Talk

27 nov 2025, 11:07 UTC

Utili

Genting: Positive About Prospects Over Longer Term

27 nov 2025, 11:06 UTC

Utili

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 nov 2025, 11:04 UTC

Utili

Genting: International Travel Demand Expected to Remain Resilient

27 nov 2025, 11:04 UTC

Utili

Genting: Global Growth Expected to Remain Subdued

27 nov 2025, 11:04 UTC

Utili

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 nov 2025, 10:59 UTC

Utili

Genting Bhd 3Q Net Profit Fell 86% on Year

27 nov 2025, 10:58 UTC

Utili

Genting Bhd 3Q Rev Rose 14% on Year

27 nov 2025, 10:56 UTC

Utili

Genting Bhd 3Q Net MYR30.3M

27 nov 2025, 10:56 UTC

Utili

Genting Bhd 3Q EPS MYR0.0079

Confronto tra pari

Modifica del prezzo

West Pharmaceutical Services Inc Previsione

Obiettivo di Prezzo

By TipRanks

26.13% in crescita

Previsioni per 12 mesi

Media 349.56 USD  26.13%

Alto 375 USD

Basso 311 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per West Pharmaceutical Services Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

10

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

213.26 / 219.27Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

168 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its products include various primary packaging, containment solutions, reconstitution, and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services, and integrated solutions. The Company’s segments include Proprietary Products and Contract-Manufactured Products. Proprietary Products reportable segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services. Contract-Manufactured Products segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
help-icon Live chat